Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome

Neurogastroenterology and Motility

Volumn 23, Issue 10, 2011, Pages

  Whitehead, W E ^a   Palsson, O S ^a   Gangarosa, L ^a   Turner, M ^a   Tucker, J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Irritable bowel syndrome; Lubiprostone; Pain sensitivity

Indexed keywords

LUBIPROSTONE; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTICLE; BALLOON DILATATION; BAROSTAT; CONSTIPATION; CONTROLLED STUDY; DEFECATION URGENCY; DOUBLE BLIND PROCEDURE; FECES ANALYSIS; FEMALE; HUMAN; INTESTINE TRANSIT TIME; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; NOCICEPTION; PAIN THRESHOLD; PERCEPTIVE THRESHOLD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ALPROSTADIL; CROSS-OVER STUDIES; DEFECATION; DILATATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; PAIN; PAIN THRESHOLD;

EID: 80052863525     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2011.01776.x     Document Type: Article

References (19)

1. Cuppoletti J, Malinowska DH, Tewari KP et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 2004; 287: C1173-83.
2. Carter NJ, Scott LJ. Lubiprostone: in constipation-predominant irritable bowel syndrome. Drugs 2009; 69: 1229-37.
3. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: phase 2 trial of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008; 27: 685-96.
4. Drossman DA, Chey WD, Johanson JF et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29: 329-41.
5. Sweetser S, Busciglio IA, Camilleri M et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol 2009; 296: G295-301.
6. Drossman DA, Toner BB, Whitehead WE et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterol 2003; 125: 19-31.
7. Rivkin A, Chagan L. Lubiprostone: chloride channel activator for chronic constipation. Clin Ther 2006; 28: 2008-21.
8. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007; 25: 1351-61.
9. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997; 11: 395-402.
10. Kanazawa M, Palsson OS, Thiwan SIM et al. Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. 2008; 103: 2550-61.
11. Whitehead WE, Crowell MD, Davidoff AL, Palsson OS, Schuster MM. Pain from rectal distension in women with irritable bowel syndrome: relationship to sexual abuse. Dig Dis Sci 1997; 42: 796-804.
12. Dorn SD, Palsson OS, Thiwan SI et al. Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut 2007; 56: 1202-9.
13. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32: 920-4.
14. Spiegel B, Camilleri M, Bolus R et al. Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report. Gastroenterology 2009; 137: 1944-53.
15. Kennedy TM, Chalder T, McCrone P et al. Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial. Health Technol Assess 2006; 10(19).
16. Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ 2009; 339: b3154.
17. Abrahamsson H, Antov S, Bosaeus I. Gastrointestinal and colonic segmental transit time evaluated by a single abdominal x-ray in healthy subjects and constipated patients. Scand J Gastroenterol Suppl 1988; 152: 72-80.
18. Camilleri M, Bharucha AE, Ueno R et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006; 290: G942-7.
19. Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Phase III. Randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation. 126 ed. 2004: A100.